Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Aug 2;2(8):e198890.
doi: 10.1001/jamanetworkopen.2019.8890.

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis

Raluca I Mincu  1 , Amir A Mahabadi  1 , Lars Michel  1 , Simone M Mrotzek  1 , Dirk Schadendorf  2 , Tienush Rassaf  1 , Matthias Totzeck  1
Affiliations
Meta-Analysis

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis

Raluca I Mincu et al. JAMA Netw Open. .

Abstract

Importance: Cardiovascular adverse events (CVAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized.

Objective: To determine the association of BRAF and MEK inhibitor treatment with CVAEs in patients with melanoma compared with BRAF inhibitor monotherapy.

Data sources: PubMed, Cochrane, and Web of Science were systematically searched for keywords vemurafenib, dabrafenib, encorafenib, trametinib, binimetinib, and cobinimetinib from database inception through November 30, 2018.

Study selection: Randomized clinical trials reporting on CVAEs in patients with melanoma being treated with BRAF and MEK inhibitors compared with patients with melanoma being treated with BRAF inhibitor monotherapy were selected.

Data extraction and synthesis: Data assessment followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. Pooled relative risks (RRs) and 95% CIs were determined using random-effects and fixed-effects analyses. Subgroup analyses were conducted to assess study-level characteristics associated with CVAEs.

Main outcomes and measures: The selected end points were pulmonary embolism, a decrease in left ventricular ejection fraction, arterial hypertension, myocardial infarction, atrial fibrillation, and QTc interval prolongation. All-grade and high-grade (≥3) CVAEs were recorded.

Results: Overall, 5 randomized clinical trials including 2317 patients with melanoma were selected. Treatment with BRAF and MEK inhibitors was associated with an increased risk of pulmonary embolism (RR, 4.36; 95% CI, 1.23-15.44; P = .02), a decrease in left ventricular ejection fraction (RR, 3.72; 95% CI, 1.74-7.94; P < .001), and arterial hypertension (RR, 1.49; 95% CI, 1.12-1.97; P = .005) compared with BRAF inhibitor monotherapy. The RRs for myocardial infarction, atrial fibrillation, and QTc prolongation were similar between the groups. These results were consistent when assessing high-grade CVAEs (left ventricular ejection fraction: RR, 2.79; 95% CI, 1.36-5.73; P = .005; I2 = 29%; high-grade arterial hypertension: RR, 1.54; 95% CI, 1.14-2.08; P = .005; I2 = 0%), but RRs for high-grade pulmonary embolism were similar between groups. A higher risk of a decrease in left ventricular ejection fraction was associated with patients with a mean age younger than 55 years (RR, 26.50; 95% CI, 3.58-196.10; P = .001), and the associated risk of pulmonary embolism was higher for patients with a mean follow-up time longer than 15 months (RR, 7.70; 95% CI, 1.40-42.12; P = .02).

Conclusions and relevance: Therapy with BRAF and MEK inhibitors was associated with a higher risk of CVAEs compared with BRAF inhibitor monotherapy. The findings may help to balance between beneficial melanoma treatment and cardiovascular morbidity and mortality.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Schadendorf reported receiving patient fees from the University Hospital Essen during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. PRISMA Selection Flowchart
Figure 2.
Figure 2.. Overall Study Estimates of the Risk Ratio (RR) of Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitor Treatment vs BRAF Inhibitor Monotherapy
LVEF indicates left ventricular ejection fraction.
Figure 3.
Figure 3.. Overall and Individual Study Estimates of the Risk Ratio (RR) for a Decrease in Left Ventricular Ejection Fraction and Arterial Hypertension Associated With BRAF and MEK Inhibitor Treatment vs BRAF Inhibitor Monotherapy
See this image and copyright information in PMC

References

    1. Schadendorf D, van Akkooi ACJ, Berking C, et al. . Melanoma. Lancet. 2018;392(10151):-. doi:10.1016/S0140-6736(18)31559-9 - DOI - PubMed
    1. Bronte E, Bronte G, Novo G, et al. . What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget. 2015;6(34):35589-35601. doi:10.18632/oncotarget.5853 - DOI - PMC - PubMed
    1. Davies H, Bignell GR, Cox C, et al. . Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. doi:10.1038/nature00766 - DOI - PubMed
    1. Schadendorf D, Long GV, Stroiakovski D, et al. . Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017;82:45-55. doi:10.1016/j.ejca.2017.05.033 - DOI - PubMed
    1. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772-774. doi:10.1056/NEJMcibr1013704 - DOI - PubMed

MeSH terms